{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:07:40Z","timestamp":1793815660294,"version":"4.6.1"},"reference-count":25,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Institute, National Institutes of Health","award":["Contract No. HHSN261200800001E"],"award-info":[{"award-number":["Contract No. HHSN261200800001E"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0680-3","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T07:02:44Z","timestamp":1564038164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1\u20133 inhibitor, cediranib, in recurrent women\u2019s cancers with biomarker analyses"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6789-0982","authenticated-orcid":false,"given":"Alexandra S.","family":"Zimmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Cimino-Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Peer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise C.","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Lipkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane B.","family":"Trepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajni","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekha","family":"Mikkilineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Gatti-Mays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole D.","family":"Houston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,7,25]]},"reference":[{"issue":"1","key":"680_CR1","first-page":"67","volume":"30","author":"L J-m","year":"2016","unstructured":"J-m L, Ivy SP, Kohn EC. Challenges and opportunities for immunotherapies in gynecologic cancers. Oncology New York. 2016;30(1):67\u20139.","journal-title":"Oncology New York"},{"issue":"7","key":"680_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","volume":"7","author":"KW Mouw","year":"2017","unstructured":"Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7(7):675\u201393.","journal-title":"Cancer Discov"},{"issue":"5","key":"680_CR3","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","volume":"33","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Nathanson T, Rizvi H, et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung Cancer. Cancer Cell. 2018;33(5):843\u2013+.","journal-title":"Cancer Cell"},{"issue":"14","key":"680_CR4","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","volume":"23","author":"S Jiao","year":"2017","unstructured":"Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances Cancer-associated immunosuppression. Clin Cancer Res. 2017;23(14):3711\u201320.","journal-title":"Clin Cancer Res"},{"key":"680_CR5","doi-asserted-by":"crossref","unstructured":"Sun C, Fang Y, Yin J, et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med. 2017;9(392).","DOI":"10.1126\/scitranslmed.aal5148"},{"issue":"5","key":"680_CR6","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1073\/pnas.0904783107","volume":"107","author":"DC Hegan","year":"2010","unstructured":"Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, Glazer PM. Inhibition of poly (ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci U S A. 2010;107(5):2201\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"680_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/82_2010_95","volume":"344","author":"LE Kandalaft","year":"2011","unstructured":"Kandalaft LE, Motz GT, Busch J, Coukos G. Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin. Cancer Immunol Immunother. 2011;344:129\u201348.","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"680_CR8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","volume":"15","author":"JF Liu","year":"2014","unstructured":"Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15(11):1207\u201314.","journal-title":"Lancet Oncol"},{"key":"680_CR9","doi-asserted-by":"publisher","first-page":"175883591880415","DOI":"10.1177\/1758835918804151","volume":"10","author":"N Munoz-Unceta","year":"2018","unstructured":"Munoz-Unceta N, Burgueno I, Jimenez E, Paz-Ares L. Durvalumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2018;10:1758835918804151.","journal-title":"Ther Adv Med Oncol"},{"issue":"19","key":"680_CR10","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1200\/JCO.2016.72.1340","volume":"35","author":"J-M Lee","year":"2017","unstructured":"Lee J-M, Cimino-Mathews A, Peer CJ, et al. Safety and clinical activity of the programmed death-ligand 1 inhibitor Durvalumab in combination with poly (ADP-ribose) polymerase inhibitor Olaparib or vascular endothelial growth factor receptor 1-3 inhibitor Cediranib in Women\u2019s cancers: a dose-escalation, phase I study. J Clin Oncol. 2017;35(19):2193\u2013+.","journal-title":"J Clin Oncol"},{"issue":"2","key":"680_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/chromatography1020082","volume":"1","author":"Jeffrey Roth","year":"2014","unstructured":"Roth J, Peer CJ, Mannargudi B, et al. A sensitive and robust ultra HPLC assay with tandem mass spectrometric detection for the quantitation of the PARP inhibitor Olaparib (AZD2281) in human plasma for pharmacokinetic application. Chromatography. 2014;(1):82\u201395.","journal-title":"Chromatography"},{"issue":"2","key":"680_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","volume":"15","author":"A Rajan","year":"2014","unstructured":"Rajan A, Carter CA, Berman A, et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014;15(2):191\u2013200.","journal-title":"Lancet Oncol"},{"issue":"11","key":"680_CR13","doi-asserted-by":"publisher","first-page":"e1219008","DOI":"10.1080\/2162402X.2016.1219008","volume":"5","author":"Y Tomita","year":"2016","unstructured":"Tomita Y, Lee MJ, Lee S, et al. The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat. Oncoimmunology. 2016;5(11):e1219008.","journal-title":"Oncoimmunology"},{"key":"680_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fonc.2015.00123","volume":"5","author":"J-M Lee","year":"2015","unstructured":"Lee J-M, Trepel JB, Choyke P, et al. CECs and IL-8 have prognostic and predictive utility in patients with recurrent platinum-sensitive ovarian cancer: biomarker correlates from the randomized phase-2 trial of olaparib and cediranib compared with olaparib in recurrent platinum-sensitive ovarian cancer. Front Oncol. 2015;5:123.","journal-title":"Front Oncol"},{"issue":"9","key":"680_CR15","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","volume":"12","author":"KA Gelmon","year":"2011","unstructured":"Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852\u201361.","journal-title":"Lancet Oncol"},{"issue":"33","key":"680_CR16","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","volume":"27","author":"UA Matulonis","year":"2009","unstructured":"Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an Oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal Cancer. J Clin Oncol. 2009;27(33):5601\u20136.","journal-title":"J Clin Oncol"},{"key":"680_CR17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2018.04.554","volume":"149","author":"P Konstantinopoulos","year":"2018","unstructured":"Konstantinopoulos P, Munster P, Forero-Torez A, et al. Topacio: preliminary activity and safety in patients (pts) with platinum-resistant ovarian cancer (PROC) in a phase 1\/2 study of niraparib in combination with pembrolizumab. Gynecol Oncol. 2018;149:246.","journal-title":"Gynecol Oncol"},{"key":"680_CR18","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2018.04.555","volume":"149","author":"Y Drew","year":"2018","unstructured":"Drew Y, de Jonge M, Hong S, et al. An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC). Gynecol Oncol. 2018;149:246\u20137.","journal-title":"Gynecol Oncol"},{"key":"680_CR19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/annonc\/mdx768","volume":"29","author":"J Lee","year":"2018","unstructured":"Lee J, Annunziata C, Houston N, et al. A phase 2 study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa). Ann Oncol. 2018;29:332\u201358.","journal-title":"Ann Oncol"},{"key":"680_CR20","doi-asserted-by":"crossref","unstructured":"Liu J, Herold C, Luo W, et al. A phase 2 trial of combination nivolumab and bevacizumab in recurrent ovarian cancer. Ann Oncol. 2018;29.","DOI":"10.1093\/annonc\/mdy285.146"},{"issue":"15_suppl","key":"680_CR21","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1200\/JCO.2017.35.15_suppl.5513","volume":"35","author":"Andrea Varga","year":"2017","unstructured":"Varga A, Piha-Paul SA, Ott PA, et al. Pembrolizumab in patients (pts) with PD-L1-positive (PD-L1(+)) advanced ovarian cancer: updated analysis of KEYNOTE-028. J Clin Oncol. 2017;35.","journal-title":"Journal of Clinical Oncology"},{"key":"680_CR22","doi-asserted-by":"crossref","unstructured":"Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast Cancer. N Engl J Med. 2018.","DOI":"10.1056\/NEJMoa1809615"},{"key":"680_CR23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-017-0479-y","volume":"10","author":"D Liu","year":"2017","unstructured":"Liu D, Wang S, Bindeman W. Clinical applications of PD-L1 bioassays for cancer immunotherapy. J Hematol Oncol. 2017;10:110.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"680_CR24","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","volume":"12","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung Cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol. 2017;12(2):208\u201322.","journal-title":"J Thorac Oncol"},{"issue":"17","key":"680_CR25","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1158\/1078-0432.CCR-16-0698","volume":"23","author":"RE Vilain","year":"2017","unstructured":"Vilain RE, Menzies AM, Wilmott JS, et al. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. Clin Cancer Res. 2017;23(17):5024\u201333.","journal-title":"Clin Cancer Res"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0680-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0680-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0680-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:44:50Z","timestamp":1601041490000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0680-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,25]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["680"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0680-3","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,25]]},"assertion":[{"value":"6 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This clinical trial was approved by the NIH IRB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients enrolled in the clinical trial signed Informed Consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"197"}}